Search Within

David Hyman

  1. "Mrinal Gounder"
Formats
  1. Journal Article (15)
  2. Meeting Abstract (6)
Groups
  1. Department of Medicine (21)
  2. Early Drug Development Service (21)
  3. Sarcoma Service (21)
  4. Solid Tumor Oncology Division (21)
  5. Epidemiology and Biostatistics (15)
  6. Biostatistics Service (14)

More Groups

People
  1. Mrinal Gounder (21)
  2. Alexander Drilon (10)
  3. Alexia Iasonos (9)
  4. David Spriggs (9)
  5. Anne Eaton (7)
  6. James Harding (7)

More People

Years
  1. 2021 (1)
  2. 2020 (2)
  3. 2018 (2)
  4. 2017 (4)
  5. 2016 (4)
  6. 2015 (4)

More Years

Publications
  1. Journal of Clinical Oncology (7)
  2. Clinical Cancer Research (3)
  3. Annals of Oncology (2)
  4. Cancer (2)
  5. Investigational New Drugs (2)
  6. Blood (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (8)
  2. American Association for Cancer Research (3)
  3. Nature Publishing Group (2)
  4. Oxford University Press (2)
  5. Springer (2)
  6. Wiley Blackwell (2)

More Publishers

Results (21)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Characterization and management of ERK inhibitor associated dermatologic adverse events: Analysis from a nonrandomized trial of ulixertinib for advanced cancers
    Journal Article

    Wu, J.; Liu, D.; Offin, M.; Lezcano, C.; Torrisi, J. M.; Brownstein, S.; Hyman, D. M.; Gounder, M. M.; Abida, W.; Drilon, A.; more...
    Investigational New Drugs (2021)

    Fulltext@MSK | Save
  • Clinical implications of drug-induced liver injury in early-phase oncology clinical trials
    Journal Article

    Mondaca, S. P.; Liu, D.; Flynn, J. R.; Badson, S.; Hamaway, S.; Gounder, M. M.; Khalil, D. N.; Drilon, A. E.; Li, B. T.; Jhaveri, K. L.; more...
    Cancer (2020)

    Fulltext@MSK | Save
  • Characterization of on-target adverse events caused by TRK inhibitor therapy
    Journal Article

    Liu, D.; Flory, J.; Lin, A.; Offin, M.; Falcon, C. J.; Murciano-Goroff, Y. R.; Rosen, E.; Guo, R.; Basu, E.; Li, B. T.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L)
    Meeting Abstract

    Bauer, T. M.; Gounder, M. M.; Weise, A. M.; Schwartz, G. K.; Carvajal, R. D.; Kumar, P.; Zernovak, O.; Beck, A.; Doyle, J.; Mendell-Harary, J.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials
    Journal Article

    Yokota, T.; Bendell, J.; Lorusso, P.; Tsushima, T.; Desai, V.; Kenmotsu, H.; Watanabe, J.; Ono, A.; Murugesan, B.; Silva, J.; more...
    British Journal of Cancer (2018)

    Fulltext@MSK | Save
  • OncoKB: A precision oncology knowledge base
    Journal Article

    Chakravarty, D.; Gao, J.; Phillips, S.; Kundra, R.; Zhang, H.; Wang, J.; Rudolph, J. E.; Yaeger, R.; Soumerai, T.; Nissan, M. H.; more...
    JCO Precision Oncology (2017)

    Fulltext@MSK | Save
  • A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
    Journal Article

    Smyth, L. M.; Monson, K. R.; Jhaveri, K.; Drilon, A.; Li, B. T.; Abida, W.; Iyer, G.; Gerecitano, J. F.; Gounder, M.; Harding, J. J.; more...
    Investigational New Drugs (2017)

    Fulltext@MSK | Save
  • The PARP inhibitor veliparib can be safely added to bendamustine and rituximab and has preliminary evidence of activity in B-cell lymphoma
    Journal Article

    Soumerai, J. D.; Zelenetz, A. D.; Moskowitz, C. H.; Palomba, M. L.; Hamlin, P. A. Jr; Noy, A.; Straus, D. J.; Moskowitz, A. J.; Younes, A.; Matasar, M. J.; more...
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save
  • Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
    Journal Article

    Zehir, A.; Benayed, R.; Shah, R. H.; Syed, A.; Middha, S.; Kim, H. R.; Srinivasan, P.; Gao, J.; Chakravarty, D.; Devlin, S. M.; more...
    Nature Medicine (2017)

    Fulltext@MSK | Save
  • A phase 1 study of the MDM2 inhibitor DS-3032b in patients (pts) with advanced solid tumors and lymphomas
    Meeting Abstract

    Gounder, M. M.; Bauer, T. M.; Schwartz, G. K.; Masters, T.; Carvajal, R. D.; Song, S.; Kumar, P.; Gajee, R.; Zernovak, O.; Rosen, M. M.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save